Accreditation and Disclosure Information

Please read the accreditation and disclosure information, then scroll down and click the “Mark Complete” button.  You may then proceed to the pre-assessment.

TARGET AUDIENCE
Hematologists-oncologists, oncologists, physician assistants, pharmacists, nurse practitioners, nurses, and oncology social workers at the intermediate and advanced levels involved in the care of patients with hematologic malignancies.

LEARNING OBJECTIVES
At the conclusion of this program, participants will be able to:

  • Describe the latest developments in immunotherapy for patients with relapsed/refractory blood cancer
  • Explain the emerging role of chimeric antigen receptor (CAR) T-cell treatment options
  • Discuss treatment plans for patient care
  • Explain potential short- and long-term side effects and management
  • Be more prepared to identify patients who could potentially be treated with CAR therapy
  • Engage patients and caregivers in discussions on CAR T-cell therapies including benefits, risks, and barriers to entry

PROVIDERS
This activity is jointly provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT
This activity is supported by educational grants from Juno, a Celgene Company and Kite, a Gilead Company.

PHARMACY CREDIT DESIGNATION
The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 5.0 contact hours (0.5 CEUs) of continuing pharmacy education credit.
The Universal Activity Number for this activity is 0468-9999-18-007-H01-P.

DISCLOSURES
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s):  honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.  All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society, the accredited providers for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CPE/CE activity for any amount during the past 12 months.

Name of Planner or Manager Title Reported Financial Relationship
Amar Assal, MD Content Expert Reviewer Amar Assal, MD, Content Expert Reviewer, has nothing to disclose.

DISCLAIMER
The information provided at this CME/CPE/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines.  No bias towards or promotion for any agent discussed in this activity should be inferred.

FACULTY DISCLOSURES

David L. Porter, MD, is a consultant for Kite and Novartis Pharmaceuticals.  He also has done research and IP for Novartis. His spouse is employed with Genentech.  He does intend to include either non-FDA-approved or investigational use for the following products/devices:  CAR T-cells for cancer.

Jennifer N. Brudno, MD, has nothing to disclose.  She does intend to discuss either non-FDA-approved or investigational use for the following products/devices:  off label of Eltrombopag for CAR T-cell induced cytopenias and CAR T-cell therapy for multiple myeloma.

Stephanie Farnia, MPH, has nothing to disclose. She does not intend to include any non-FDA-approved or investigational use of any products/devices.

Noelle Frey, MD, MS, is on the advisory board for Novartis. She does intend to include either non-FDA-approved or investigational use for the following products/devices:  novel agents currently in clinical trial for CAR T-cell.

Saar I. Gill, MD, PhD, has done research for Novartis and has stock in CARMA Therapeutics.  He does intend to include either non-FDA-approved or investigational use for the following products/devices:  novel agents currently in clinical trial for CAR T-cell.

Sergio A. Giralt, MD, is a consultant for: Adecco, Celgene, Jazz and Kite Pharmaceuticals.  He has done research for Takeda.  He does not intend to include any non-FDA-approved or investigational use of any products/devices.

Stephan A. Grupp, MD, PhD, is a consultant for Novartis.  He does not intend to include any non-FDA-approved or investigational use of any products/devices.

Stephen J. Schuster, MD, is a consultant for: Celgene, Dava Oncology, Genentech, Gilead, Janssen, Merck, Novartis, Nordic Nanovector, Pharmacyclics and Seattle Genetics. Research for:  Celgene, Genentech, Janssen, Merck, Novartis, Pharmacyclics and Seattle Genetics.  Advisory Board for: Celgene, Genentech, Gilead, Janssen, Merck, Novartis, Nordic Nanovector, Pharmacyclics, and Seattle Genetics. Steering Committee: Celgene, Novartis and Pharmacyclics.  He does intend to include either non-FDA-approved or investigational use for the following products/devices:  CAR T-cells.

LLS DISCLOSURES

Gwen Nichols, MD, is a former employee for Hoffman La Roche.  She does not intend to include any non-FDA-approved or investigational use of any products/devices.

Margaret McCormick, RN, BSN, MA, MBA, has nothing to disclose. She does not intend to include any non-FDA-approved or investigational use of any products/devices.

Holly McConville, RN, BSN, has nothing to disclose. She does intend to include either non-FDA-approved or investigational use for the following products/devices:  novel agents currently in clinical trial for CAR T-cell.